Topoisomerase IIα in chromosome instability and personalized cancer therapy.
about
Emerging molecular classifications and therapeutic implications for gastric cancerOncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis.Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast CancerTop2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.Quantitative interactome analysis reveals a chemoresistant edgotype.Stacked thin layers of metaphase chromatin explain the geometry of chromosome rearrangements and bandingLong-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.PTEN stabilizes TOP2A and regulates the DNA decatenationThe dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religationTargeting of topoisomerases for prognosis and drug resistance in ovarian cancer.ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication.Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer ProgressionPredictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data.Omics-Based Platform for Studying Chemical Toxicity Using Stem Cells.Genome-scale regression analysis reveals a linear relationship for promoters and enhancers after combinatorial drug treatment.The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes.Toxicodynamics of Mycotoxins in the Framework of Food Risk Assessment-An In Silico Perspective.Importin-β and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function.The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity.Exploration of gene functions for esophageal squamous cell carcinoma using network-based guilt by association principle.Identification of Common Genes Refers to Colorectal Carcinogenesis with Paired Cancer and Noncancer Samples.The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.Genomic alterations of ground-glass nodular lung adenocarcinoma.Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain.Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127).Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90.DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chlorideSmurfs in Protein Homeostasis, Signaling, and Cancer
P2860
Q26745525-65B95E78-9E8A-4DB4-8B83-DD012EE60603Q30252747-58CEC0C1-B7D9-4FFF-9BE3-95284174734EQ31015478-5F53EE4E-B886-4A85-BC38-EAFC8DDD1966Q35550192-79EC49B6-4A71-4EF4-9CA6-17BFDB36E868Q35941833-6F57E17E-7949-408F-A72E-EDD444235224Q36134216-8455D59D-2B29-4207-B953-46456C32DA93Q36316604-E97BC432-9D40-4D1A-992D-4091C8C26054Q36360788-631DB551-39A7-4B4C-A41F-B6DBE3D9D75FQ36545904-D5DB5F67-4C25-4328-A5E9-D6EC77CE89BAQ37018096-9F2B7AEF-18CE-4B4C-AD42-FCDF9E2DBCE5Q37508792-9988EDA1-0CE8-4D71-9725-D193763BE2CFQ38660811-7497D35F-C583-4D85-99E0-34B53EDC2D10Q38810286-FA50A8BE-29F2-4403-8E33-1EE3E0406BE9Q38820055-7AC123D3-D1A5-4A31-9786-72D306525AB9Q38922208-31E1A8F6-D0D1-4BF6-B264-90BACBF56C52Q39305667-99B68623-7060-4CB7-A325-8C41D7AFFBD7Q39565398-39BB7501-EB49-4EDC-8489-754A8ADA94E9Q41143898-170DBB01-0794-4253-BD09-99521DDD5478Q41367937-A58B2708-9FB8-4293-96D6-433C216A3DE6Q42234159-218C26FF-CE1E-46FC-A517-24FEF1D5DEC1Q47100137-BF9A3296-C6ED-4F81-B753-4BFE3BCD296FQ47271495-1940FA86-CBD5-40FC-8C41-7FE7D7BD9199Q47317874-AE7013A1-07F1-44E6-A14E-207CD869B48EQ48147735-DF28B817-0AFC-48BB-BB97-447C821BF112Q48184670-C5FA2407-9FD2-4EEB-A12B-5EF22AAA021AQ48297889-E041B2AF-544C-43DE-AEE3-34FE6AD8FA22Q50074512-91C37D01-3751-4E20-908F-C03CA8A99229Q52563670-50E467BF-4367-46D1-9890-C37AA34FD445Q52590737-8FD4CFA4-03F9-4846-A8B7-0C2EDF7D45C0Q52627272-61492C0F-BA5B-4628-BD26-3BCF72BAE0ECQ54209531-F490733E-AA36-497D-927B-5A789929455BQ54977757-25A105BE-BCD5-488B-AC8E-40529088C7C8Q55343482-C063A59A-8E33-46FE-A5E6-5F568F6633A6Q55392177-6EB654C6-D617-4F5E-8485-B455CDDA604EQ55515481-3781FEF6-FB57-4F17-A67D-DDF9A12403ADQ58724813-9F7DB2D3-8937-4674-8043-1ED15D4285F6Q58803474-C12E9777-94D5-41C1-B36A-FC3FC4E53058
P2860
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@ast
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@en
type
label
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@ast
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@en
prefLabel
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@ast
Topoisomerase IIα in chromosome instability and personalized cancer therapy.
@en
P2093
P2860
P921
P356
P1433
P1476
Topoisomerase IIα in chromosome instability and personalized cancer therapy
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2014.332
P407
P50
P577
2014-10-20T00:00:00Z